Clinical trialsHere is my take on this...2 scenarios in my opinion. 1st possibility PMN goes solo in the clinicals relying on the money they have set aside. At the first indication that the antibodies are working , there will be a frenzy of companies trying to buy the AD platform ... 2nd possibility .. as soon as PMN puts the papers in indicating their intent to proceed with clinicals,, a jv partner steps in and offers to cover a good portion of the clinicals... this jv partner would have first right of refusal if the drug is showing like it works. I personally think the second possibility is the best option for a company that doesn't want
to take PMN on chance before trials but still gets first grab if things are working out. What it also allows is for the jv partner to possibly have important data sooner then the competitors.